금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Vanguard Total Bond Market ETF Tops iShares 3-7 Year Treasury Bond ETF on Yield and Cost. Does That make BND a Buy?
Compare diversification, risk, and performance between these two leading fixed-income ETFs to see wh...
The AI Power Crisis Is Creating a Massive New Market for Fuel Cells
Data center developers are scrambling for reliable power, turning away from congested grids and towa...
Jefferies updates Franchise Picks list, adding AMZN, APP, MCD and more
I inherited a house. My CPA says I should sell within a year to avoid capital gains. Is he right?
“We plan to sell it to another family member for the appraised value.”
Buy 5 AI-Powered Internet Software Laggards for Huge Short-Term Upside
AI-powered Internet software laggards like PLTR, CRM, TEAM, NET and HUBS offer strong short-term upside as SaaS demand and AI adoption accelerate.
Victoria’s Secret & Co. Issues Letter to Shareholders Highlighting Strong Performance, Significant Shareholder Value Creation and Continued Momentum Under Current Leadership
Urges Shareholders to Vote “FOR” All Highly Qualified Directors at the 2026 Annual Meeting of ShareholdersREYNOLDSBURG, Ohio, May 18, 2026 (GLOBE NEWSWIRE) -- Victoria’s Secret & Co. (“VS&Co” or the “ ...
Lam Research gets an upgrade, Applied Materials cut at Morgan Stanley
Alaska LNG secures gas supply deal with ConocoPhillips for pipeline project
Inflation Uptick Is Starting to Send Sell Signals to Stock Bulls
(Bloomberg) -- Wall Street strategists are warning the honeymoon period for stocks following a blockbuster earnings season is over and that a harsh macro-economic reality now threatens this year’s ral ...
The Best Vanguard ETF to Invest $2,000 in This May
Even as it trades in record territory, this investment vehicle is a smart option for those ready to put money to work this month.
Nvidia in spotlight as GF Securities ups price target ahead of Q1 results
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda
A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.
At a glance: stocks gapping up premarket
Anglo American to sell Australian steelmaking coal mines for up to $3.875B